Marketing authorisation application

Colin Kerr

Published: Saturday, February 1, 2020

Aerie Pharmaceuticals has submitted the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the European Medicines Agency (EMA). Roclanda® is currently marketed in the US as Rocklatan®. ”As EMA review of the Roclanda® MAA begins, we will be completing and analysing our Mercury 3 study, which compares Roclanda®to the leading fixed-dose combination product in the EU,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie. www.aeriepharma.com

Latest Articles

Thinking Beyond Optics: Diversity, Equity, and Inclusion (DEI) and Unconscious Bias in Ophthalmology

Beyond Sight: A Clearer Vision for Equity in Ophthalmology

Refractions of Bias: Seeing DEI Clearly in Ophthalmology

Happy Patients, Higher Volumes

Digitalisation reduces errors and saves time, making a surgeon’s life easier.

Addressing Postoperative Visual Complications

Managing aberrations after laser refractive surgery requires a multi-layered approach.

3D Printing Helps Transform Ukrainian Eye Care

The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.

Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation

Emerging Microbial Trends That Could Affect Your Practices

A triptych of challenges paints a concerning picture for ophthalmologists across the globe.

Improving Outcomes with Laser-Assisted Surgery

Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.

Could the Corneal Transplant Pool Increase?

Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.